Advertisement
Abstract| Volume 92, SUPPLEMENT 1, S15-S16, March 2018

Engineering high affinity, soluble T cell receptors for the treatment of cancer

DOI:https://doi.org/10.1016/j.ejca.2018.01.039
Engineering high affinity, soluble T cell receptors for the treatment of cancer
Previous ArticleImmune modulation of AML-blasts in therapy-refractory AML-patient in vivo with clinically approved response modifiers improves clinical status, blood cell regeneration and gives rise to leukemia specific adaptive and innate immune reactive cells
Next Article4SC-202 increases immunogenicity of tumor cells, induces infiltration of tumor microenvironment with cytotoxic T cells, and primes tumors for cancer immunotherapy
      Background: T cell receptors (TCRs) bind short peptide fragments derived from endogenously processed proteins that are presented at the cell surface by human leukocyte antigens (HLAs). Natural cancer-specific TCRs have weak affinities for their cognate peptide-HLA (pHLA) complexes, preventing effective T cell mediated tumour clearance. At Immunocore we have developed a new class of bi-specifics, which comprise a soluble, high-affinity TCR targeting a specific cancer-associated pHLA, fused to an anti-CD3 scFv domain. These potent Immune mobilising monoclonal TCRs Against Cancer (ImmTAC) molecules can detect low peptide levels on cancer cells and recruit neighbouring T cells via CD3, leading to the targeted killing of malignant cells.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Register: Create an account
      Institutional Access: Sign in to ScienceDirect

      Article info

      Publication history

      P05. Combination therapy P05.01

      Identification

      DOI: https://doi.org/10.1016/j.ejca.2018.01.039

      Copyright

      © 2018 Published by Elsevier Inc.

      ScienceDirect

      Access this article on ScienceDirect
      We use cookies to help provide and enhance our service and tailor content. To update your cookie settings, please visit the for this site.
      Copyright © 2023 Elsevier Inc. except certain content provided by third parties. The content on this site is intended for healthcare professionals.


      RELX